References
- Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br J Hematol. 2016;172(4):512–523.
- Gu S, Zhao Y, Guo J, et al. High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome. Tumor Biol. 2014;35:2211–2218.
- Fragasso A, Ciancio A, Mannarella C, et al. Myocardial iron overload assessed by magnetic resonance imaging (MRI) T2* in multi-transfused patients with thalassemia and acquired anemias. Eur J Intern Med. 2011;22(1):62–65.
- Armand P, Kim HT, Rhodes J, et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):852–860.
- Abbass G, Farhan S, Nadeem MA, et al. Frequency of iron overload in patients of chronic hepatitis C undergoing therapy and treatment response in patients with iron overload. Pakistan J Med Health Sci. 2016;10(2):399–401.
- Hematology Branch of the Chinese Medical Association. MDS diagnosis and treatment expert consensus 2012. Chin J Hematol. 2012;33:347–352.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Gattermann N, Rachmilewitz EA. Iron overload in MDS pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1–10.
- Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603.
- Kountouras D, Tsagarakis NJ, Fatourou E, et al. Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver Int. 2013;33:420–427.
- Abeid ZK, Al-Tu'ma FJ, Al-Naffi KO. Polymorphism of HFE gene in ischemic heart diseases and its relation with iron overload. Ijppr Human. 2017;8(3):31–41.
- Angelucci E, Cianciulli P, Finelli C, et al. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leuk Res. 2017;62:108–115.
- Cui R, Gale RP, Zhu G, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38(5):545–550.
- Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood. 2015;126(17):2031–2037.
- Cancado R, Watman NP, Lobo C, et al. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study. Hematology. 2018;23(9):676–682.
- Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973–2978.
- Zhang Y. Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron overloaded low-risk myelodysplastic syndrome patients. Hematology. 2020;25(1):1–10.
- Girellid D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol. 2009;51(5):845–852.